The HR for QVA@ versus placebo showed no significant increase in the overall risk for death ( HR -LSB- @ % confidence interval -RSB- : @ -LSB- @-@ @ -RSB- ) ; CCV events ( @ -LSB- @-@ @ -RSB- ) ; MACE ( @ -LSB- @-@ @ -RSB- ) ; pneumonia ( @ -LSB- @-@ @ -RSB- ) ; COPD exacerbations ( @ -LSB- @-@ @ -RSB- ) ; and AF/F ( @ -LSB- @-@ @ -RSB- ) .